• Ensysce highlighted its TAAP and MPAR platforms aimed at opioids with abuse deterrence and oral overdose protection using trypsin-controlled drug release.
• PF614-MPAR development plan targets Phase 1b SAD continuation in 2026, a Phase 3 efficacy-safety study in 2026, NDA filing in 2028.
• Breakthrough Therapy designation cited for a TAAP oxycodone combination product, granted by the FDA in January 2024.
• Cy Biopharma unit outlined CY200/201 for complex regional pain syndrome, citing FDA orphan drug designation in 2026.
• Preclinical and early clinical summaries described overdose-related suppression of oxycodone release with nafamostat, while maintaining release at prescribed doses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.